Addex Therapeutics Ltd
| NASDAQ: ADXN | Healthcare / Biotechnology / Switzerland |
| 0.3600 | -0.0127 | -3.41% | Vol 82.57K | 1Y Perf -51.36% |
| Oct 4th, 2023 15:57 DELAYED |
| BID | 0.3413 | ASK | 0.3900 | ||
| Open | 0.3300 | Previous Close | 0.3727 | ||
| Pre-Market | - | After-Market | 0.40 | ||
| - - | 0.04 11.14% |
| Target Price | 15.00 | Analyst Rating | Hold 3.00 | |
| Potential % | 4.07K | Finscreener Ranking | — - | |
| Insiders Trans % 3/6/12 mo. | -/-/- | Value Ranking | ★+ 43.99 | |
| Insiders Value % 3/6/12 mo. | -/-/- | Growth Ranking | ★★ 45.69 | |
| Insiders Shares Cnt. % 3/6/12 mo. | -/-/- | Income Ranking | — - | |
| Price Range Ratio 52W % | 1.52 | Earnings Rating | — | |
| Market Cap | 4.63M | Earnings Date | 10th Nov 2023 | |
| Alpha | -0.05 | Standard Deviation | 0.28 | |
| Beta | 1.71 |
Today's Price Range 0.32500.3899 | 52W Range 0.33032.28 |
Summary:
Sell
| Technical Indicators: | Sell |
| Moving Averages: | Strong Sell |
| Performance | |||
|---|---|---|---|
| 1 Week | -2.68% | ||
| 1 Month | -32.11% | ||
| 3 Months | -39.60% | ||
| 6 Months | -52.41% | ||
| 1 Year | -51.36% | ||
| 3 Years | -97.16% | ||
| 5 Years | - | ||
| 10 Years | - |
| Mngmt Effectiveness | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
ROE (5Y Avg) | -49.88 | |||
ROE last 12 Months | -202.67 | |||
ROA (5Y Avg) | -39.21 | |||
ROA last 12 Months | -142.41 | |||
ROC (5Y Avg) | -111.32 | |||
ROC last 12 Months | -193.44 | |||
Return on invested Capital Q | -52.63 | |||
Return on invested Capital Y | -28.24 | |||
Assets Turnover | 0.00 | |||
Receivables Turnover | 0.60 |
| Valuation | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
| -0.20 | ||||
| 1.68 | ||||
| 14.93 | ||||
| - | ||||
| -1.10 | ||||
| -2.64 | ||||
| 1.78 | ||||
| 0.44 | ||||
| 5.85M | ||||
| Forward PE | - | |||
| PEG | - |
| Financial Strength | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
| 2.60 | ||||
| 2.80 | ||||
| 0.02 | ||||
| 0.06 | ||||
| -426.50 | ||||
| Leverage Ratio | 1.50 |
| Profitability | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
| - | ||||
| -1 753.70 | ||||
| -1 726.70 | ||||
| - | ||||
| - |
| Revenue | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
| 901.20K | ||||
| 0.05 | ||||
| -17.95 | ||||
| - |
| Dividends | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
| - | ||||
| - | ||||
| - | ||||
| - | ||||
| Payout ratio | - |
| Earnings History | Estimate | Reported | Surprise % |
|---|---|---|---|
| Q02 2023 | - | -0.25 | - |
| Q01 2023 | - | -0.26 | - |
| Q04 2022 | - | -0.25 | - |
| Q03 2022 | -0.56 | -0.56 | 0.00 |
| Q02 2022 | -0.56 | -1.18 | -110.71 |
| Q01 2022 | -0.52 | -0.97 | -86.54 |
| Q04 2021 | -0.66 | -0.83 | -25.76 |
| Q03 2021 | -0.72 | -0.72 | 0.00 |
| Earnings Per End | Estimate | Revision % | Trend |
|---|---|---|---|
| - | - | - | - |
| - | - | - | - |
| - | - | - | - |
| - | - | - | - |
| Next Report Date | 10th Nov 2023 |
| Estimated EPS Next Report | -0.20 |
| Estimates Count | 1 |
| EPS Growth Next 5 Years % | - |
| Volume Overview | |
|---|---|
| Volume | 82.57K |
| Shares Outstanding | 12.86K |
| Shares Float | 5.06M |
| Trades Count | 170 |
| Dollar Volume | 28.85K |
| Avg. Volume | 42.47K |
| Avg. Weekly Volume | 24.06K |
| Avg. Monthly Volume | 59.46K |
| Avg. Quarterly Volume | 43.90K |
Addex Therapeutics Ltd (NASDAQ: ADXN) stock closed at 0.36 per share at the end of the most recent trading day (a -3.41% change compared to the prior day closing price) with a volume of 82.57K shares and market capitalization of 4.63M. Is a component of indices and it is traded on NASDAQ exchange. The company belongs in the Biotechnology industry, Healthcare sector and employs 27 people. Addex Therapeutics Ltd CEO is Tim Dyer.
The one-year performance of Addex Therapeutics Ltd stock is -51.36%, while year-to-date (YTD) performance is -42.87%. ADXN stock has a five-year performance of %. Its 52-week range is between 0.3303 and 2.28, which gives ADXN stock a 52-week price range ratio of 1.52%
Addex Therapeutics Ltd currently has a PE ratio of -0.20, a price-to-book (PB) ratio of 1.68, a price-to-sale (PS) ratio of 14.93, a price to cashflow ratio of -, a PEG ratio of -, a ROA of -142.41%, a ROC of -193.44% and a ROE of -202.67%. The company’s profit margin is -%, its EBITDA margin is -1 726.70%, and its revenue ttm is $901.20 Thousand , which makes it $0.05 revenue per share.
Of the last four earnings reports from Addex Therapeutics Ltd, there were 0 positive earnings surprise and 0 negative earnings surprise. The company has EPS estimate of $-0.20 for the next earnings report. Addex Therapeutics Ltd’s next earnings report date is 10th Nov 2023.
The consensus rating of Wall Street analysts for Addex Therapeutics Ltd is Hold (3), with a target price of $15, which is +4 066.67% compared to the current price. The earnings rating for Addex Therapeutics Ltd stock is (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).
Addex Therapeutics Ltd has a dividend yield of -% with a dividend per share of $- and a payout ratio of -%.
Addex Therapeutics Ltd has a Sell technical analysis rating based on Technical Indicators (ADX : 7.99, ATR14 : 0.06, CCI20 : -75.72, Chaikin Money Flow : -0.38, MACD : -0.03, Money Flow Index : 40.79, ROC : -11.26, RSI : 42.56, STOCH (14,3) : 26.55, STOCH RSI : 0.90, UO : 38.63, Williams %R : -73.45), Simple Moving Averages and Exponential Moving Averages.
Aggregated Insider Trades of Addex Therapeutics Ltd in the last 12-months were:
Addex Therapeutics Ltd
Addex Therapeutics Ltd is a biopharmaceutical company. The company operates through single segment which includes developing drugs to improve human health. It is focused on the development of novel, orally available, small molecule allosteric modulators for neurological disorders. In addition, it is also engaged in the development of the dipraglurant and ADX71441 program. The company's geographical area of operations includes Switzerland and Europe.
CEO: Tim Dyer
Telephone: +41 228841555
Address: Chemin des Aulx 12, Geneva 1228, , CH
Number of employees: 27
